GlassScriptPhysician profile
Marina Sobol
NPI 1841344694
$68,568.75
in general payments reported to CMS, 2019-2025
35 companies · $1,082 in 2025
The $1,082 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,851 · 2020: $15K · 2021: $29K · 2022: $11K · 2023: $5,960 · 2024: $4,494 · 2025: $1,082.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,325 · Food and Beverage: $3,099 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,325.00 |
| Food and Beverage | $3,098.76 |
| Education | $111.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $30,811.26 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Allergan, INC. | $17,850.36 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $12,925.13 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $2,424.39 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $995.73 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Lilly USA, LLC | $810.05 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Neurocrine Biosciences, INC. | $409.97 | 2019-2025 | Ingrezza, Ongentys |
| Novartis Pharmaceuticals Corporation | $316.92 | 2019-2021 | |
| Lundbeck LLC | $294.48 | 2022-2024 | Vyepti |
| Axsome Therapeutics, INC. | $247.27 | 2025 | Symbravo |
| Biogen, INC. | $218.81 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $195.59 | 2019-2021 | |
| Eisai INC. | $172.45 | 2023-2025 | |
| Argenx US, INC. | $113.96 | 2024 | Vyvgart Hytrulo |
| Boston Scientific Corporation | $106.42 | 2025 | General - Dbs |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $102.25 | 2019-2020 | |
| Assertio Therapeutics, INC. | $100.06 | 2019-2020 | |
| Ucb, INC. | $94.07 | 2019 | |
| Upsher-Smith Laboratories LLC | $46.01 | 2019-2023 | |
| Avanir Pharmaceuticals, INC. | $43.85 | 2019-2020 | |
| Pfizer INC. | $32.02 | 2024-2025 | |
| Ge Healthcare | $29.60 | 2023-2025 | |
| Supernus Pharmaceuticals, INC. | $27.43 | 2021 | |
| Amneal Pharmaceuticals LLC | $26.22 | 2019-2020 | |
| Adamas Pharmaceuticals, INC. | $24.03 | 2019-2021 | |
| Endo Pharmaceuticals INC. | $23.52 | 2019-2021 | |
| Impel Pharmaceuticals INC. | $16.21 | 2023 | Trudhesa |
| Genzyme Corporation | $14.96 | 2019 | |
| Collegium Pharmaceutical, INC. | $14.93 | 2022 | |
| Arbor Pharmaceuticals, INC. | $14.35 | 2019 | |
| Currax Pharmaceuticals LLC | $14.12 | 2020 | |
| Genentech USA, INC. | $13.94 | 2019 | |
| Kyowa Kirin, INC. | $13.82 | 2019 | |
| Vertical Pharmaceuticals, LLC | $12.49 | 2019 | |
| Almatica Pharma LLC | $12.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marina Sobol listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.